|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
73,583,000 |
Market
Cap: |
N/A |
Last
Volume: |
1,917,000 |
Avg
Vol: |
889,275 |
52
Week Range: |
$259.55 - $259.55 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Love Richard B |
VP and General Counsel |
|
2013-05-31 |
4 |
OE |
$32.38 |
$259,040 |
D/D |
8,000 |
8,000 |
|
- |
|
Sjovall Boultbee Paula S |
EVP, Sales and Marketing |
|
2013-04-30 |
4 |
A |
$52.24 |
$21,210 |
I/I |
406 |
406 |
|
- |
|
Sjovall Boultbee Paula S |
EVP, Sales and Marketing |
|
2013-04-30 |
4 |
A |
$23.07 |
$19,378 |
D/D |
840 |
1,658 |
|
- |
|
Zanganeh Maky |
Chief Operating Officer |
|
2013-04-30 |
4 |
A |
$10.56 |
$21,241 |
D/D |
2,012 |
230,107 |
|
- |
|
Tan Heow |
Chief of Technical Operations |
|
2013-04-30 |
4 |
A |
$52.24 |
$12,381 |
D/D |
237 |
237 |
|
- |
|
Soni Manmeet Singh |
VP, Corporate Controller |
|
2013-04-30 |
4 |
A |
$52.24 |
$12,799 |
D/D |
245 |
245 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2013-04-30 |
4 |
A |
$10.56 |
$13,133 |
D/D |
1,244 |
24,236 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2013-04-30 |
4 |
A |
$10.56 |
$1,731 |
D/D |
164 |
489 |
|
- |
|
Kunkel Lori Anne |
Chief Medical Officer |
|
2013-04-30 |
4 |
A |
$23.07 |
$21,247 |
D/D |
921 |
2,842 |
|
- |
|
Gayko Urte |
Sr. VP, Regulatory |
|
2013-04-30 |
4 |
A |
$52.24 |
$21,210 |
D/D |
406 |
406 |
|
- |
|
Erdtmann Rainer M |
Sr. VP, IR and Admin |
|
2013-04-30 |
4 |
A |
$10.56 |
$21,241 |
D/D |
2,012 |
11,497 |
|
- |
|
Fardis Maria |
Chief of Oncology Ops & Allian |
|
2013-04-30 |
4 |
A |
$10.56 |
$21,241 |
D/D |
2,012 |
2,988 |
|
- |
|
Buggy Joseph J |
VP, Research |
|
2013-04-30 |
4 |
A |
$10.56 |
$21,241 |
D/D |
2,012 |
8,713 |
|
- |
|
Clow Fong Wang |
VP Biostatistics Data Mgmt |
|
2013-04-30 |
4 |
A |
$10.56 |
$21,241 |
D/D |
2,012 |
4,024 |
|
- |
|
Buggy Joseph J |
VP, Research |
|
2013-02-11 |
4 |
AS |
$69.97 |
$839,666 |
D/D |
(12,000) |
6,701 |
|
- |
|
Buggy Joseph J |
VP, Research |
|
2013-02-11 |
4 |
OE |
$0.86 |
$10,320 |
D/D |
12,000 |
18,701 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2013-02-05 |
4 |
AS |
$70.58 |
$1,411,510 |
D/D |
(20,000) |
325 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2013-02-05 |
4 |
OE |
$2.76 |
$55,200 |
D/D |
20,000 |
20,325 |
|
- |
|
Mcgreivy Jesse |
VP, Clinical Science |
|
2013-01-17 |
4 |
S |
$67.29 |
$39,229 |
D/D |
(583) |
0 |
|
- |
|
Crum Michael |
Vice President, U.S. SalesOffi |
|
2013-01-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2013-01-11 |
4 |
S |
$67.11 |
$335,550 |
D/D |
(5,000) |
22,992 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2013-01-11 |
4 |
OE |
$2.76 |
$18,471 |
D/D |
5,000 |
27,992 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2013-01-09 |
4 |
S |
$66.30 |
$698,205 |
D/D |
(10,531) |
325 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2013-01-09 |
4 |
S |
$4.16 |
$43,809 |
D/D |
(10,531) |
10,856 |
|
- |
|
Fardis Maria |
EVP, Operations and Alliances |
|
2013-01-08 |
4 |
S |
$65.00 |
$162,500 |
D/D |
(2,500) |
976 |
|
- |
|
364 Records found
|
|
Page 5 of 15 |
|
|